📰 Complete Remission News
Page 2 - Complete Remission News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Complete Remission. Real-time updates on events, politics, business and more.
June 14, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
June 12, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,...
June 8, 2023
- IO-202 (anti-LILRB4) is well tolerated, with encouraging clinical responses in both monotherapy and combination therapy - - FDA granted Fast Track designation to IO-202 for the treatment of relapsed
May 11, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
May 10, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
April 19, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,...
April 3, 2023
- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high...
March 16, 2023
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,...
March 13, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
February 22, 2023
/PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of cancer that...